Integrin β1 (ITGB1) is frequently upregulated in
ovarian cancer, and promotes ovarian
tumorigenesis and
cancer progression. However, the effects of ITGB1 inhibition on
ovarian cancer progression and anticancer
therapy remain to be elucidated. The results of the present study indicated that ITGB1 was upregulated in HO‑8910 and HO‑8910PM
ovarian cancer cell lines, and knockdown of ITGB1 using
short hairpin RNA markedly increased
tumor cell apoptosis, decreased
tumor cell adhesion and migration, and reduced
tumor cell invasion by suppressing
matrix metalloproteinase (
MMP)‑2 and MMP‑9 expression. Furthermore, the results of the present study provided evidence regarding the role of ITGB1 inhibition in
bevacizumab anticancer
therapy. The activation of signal transducer and activator of transcription 1 (STAT1) by
focal adhesion kinase (FAK) is involved in integrin‑mediated cell migration and adhesion. In the present study, the expression levels of FAK were markedly upregulated in
ovarian cancer. The adherence and migratory potentials of
ovarian cancer cells were significantly reduced when the FAK/STAT1 signaling pathway was inhibited by
fludarabine. The results of the present study demonstrated that ITGB1 inhibition effectively reduced
tumorigenesis and
disease exacerbation, and contributed to
bevacizumab anticancer
therapy via the FAK/STAT1 signaling pathway, suggesting that inhibition of ITGB1 is a potential novel therapeutic strategy for ovarian
carcinogenesis.